Dysregulated androgen receptor (AR) signaling has been identified as a key driver in prostate cancer development, which has led to the use of androgen deprivation therapy (ADT) as the mainstay treatment for advanced or metastatic disease [1]. This evidence concerns the gene AR and prostate carcinoma.